• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Nasdaq Down 50 Points; S&P Global Composite PMI Hits 26-Month High

    6/21/24 10:13:07 AM ET
    $AREB
    $KAVL
    $PBM
    $RELI
    Plastic Products
    Industrials
    Other Consumer Services
    Consumer Discretionary
    Get the next $AREB alert in real time by email

    U.S. stocks traded mixed this morning, with the Nasdaq Composite falling around 50 points on Friday.

    Following the market opening Friday, the Dow traded up 0.18% to 39,206.92 while the NASDAQ fell 0.29% to 17,669.56. The S&P 500 also fell, dropping, 0.20% to 5,461.98.

    Check This Out: Apple To Rally Over 14%? Here Are 10 Top Analyst Forecasts For Friday

    Leading and Lagging Sectors

    Consumer staples shares jumped by 0.6% on Friday.

    In trading on Friday, information technology shares fell by 1.1%.

    Top Headline

    The S&P Global composite PMI climbed to 54.6 in June, notching its strongest level since April 2022, and compared to 54.5 in May.

    Equities Trading UP
                           

    • American Rebel Holdings, Inc. (NASDAQ:AREB) shares shot up 164% to $0.8168 after the company signed a Connecticut distribution agreement with Dichello Distributors.
    • Shares of Sharecare, Inc. (NASDAQ:SHCR) got a boost, surging 75% to $1.3550 after the company agreed to be acquired by Altaris affiliate for $1.43 per share in cash.
    • Spectaire Holdings Inc. (NASDAQ:SPEC) shares were also up, gaining 76% to $0.5998. The company recently announced a purchase order and delivery of its advanced AireCore units to American Ag Energy.

    Equities Trading DOWN

    • Kaival Brands Innovations Group, Inc. (NASDAQ:KAVL) shares dropped 45% to $1.59 after the company announced pricing of $6.0 million public offering.
    • Shares of Psyence Biomedical Ltd. (NASDAQ:PBM) were down 32% to $0.4030 after gaining 6% on Thursday.
    • Reliance Global Group, Inc. (NASDAQ:RELI) was down, falling 27% to $0.4423.

    Also Check This Out:Top 3 Defensive Stocks That May Fall Off A Cliff This Quarter

    Commodities

    In commodity news, oil traded up 0.1% to $81.29 while gold traded down 0.4% at $2,360.50.

    Silver traded down 2.9% to $29.935 on Friday, while copper fell 2.4% to $4.4505.

    Euro zone

    European shares were lower today. The eurozone's STOXX 600 fell 0.9%, Germany's DAX fell 0.8% and France's CAC 40 fell 0.9%. Spain's IBEX 35 Index fell 1.6%, while London's FTSE 100 fell 0.6%.

    The Eurozone manufacturing PMI fell to 45.6 in June from 47.3 in May, while services PMI fell to 52.6 in June from 53.2 a month ago.

    The S&P Global UK composite PMI declined to 51.7 in June compared to 53.0 in May, while retail sales in the UK gained 2.9% month-over-month in May following a revised 1.8% fall in April. The HCOB Germany composite PMI fell to 50.6 in June compared to May’s reading of 52.4, while French composite PMI slipped to 48.2 from 48.9.

    Asia Pacific Markets

    Asian markets closed lower on Friday, with Japan's Nikkei falling 0.09%, Hong Kong's Hang Seng Index declining 1.67%, China's Shanghai Composite Index falling 0.24% and India's S&P BSE Sensex falling 0.1%.

    The annual inflation rate in Hong Kong rose to 1.2% in May from 1.1% in the prior month, while Hong Kong’s current account surplus widened to HKD 100.96 billion during the first quarter from HKD 44.43 billion in the year-ago period.

    The HSBC India Composite PMI climbed to 60.9 in June compared to 60.5 in the prior month, while au Jibun Bank Flash Japan composite PMI declined to 50.0 in June compared to 52.6 in May. The annual inflation rate in Japan rose to 2.8% in May versus 2.5% in the prior month.

    Economics

    • The S&P Global composite PMI climbed to 54.6 in June, notching its strongest level since April 2022, and compared to 54.5 in May.
    • The S&P Global US services PMI surged to 55.1 in June versus 54.8 a month ago.
    • The S&P Global US manufacturing PMI climbed to a three-month high level of 51.7 in June.

    Now Read This: Nvidia, Applied Materials And 2 Other Stocks Insiders Are Selling

    Get the next $AREB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AREB
    $KAVL
    $PBM
    $RELI

    CompanyDatePrice TargetRatingAnalyst
    Sharecare Inc.
    $SHCR
    4/1/2024Buy → Neutral
    BTIG Research
    Sharecare Inc.
    $SHCR
    7/20/2022$2.50Equal-Weight
    Morgan Stanley
    Sharecare Inc.
    $SHCR
    2/11/2022$4.50Neutral
    Goldman
    Sharecare Inc.
    $SHCR
    2/11/2022Neutral
    Goldman Sachs
    Reliance Global Group Inc.
    $RELI
    2/2/2022$7.00Buy
    EF Hutton
    Sharecare Inc.
    $SHCR
    8/4/2021$11.00Buy
    Canaccord Genuity
    Sharecare Inc.
    $SHCR
    7/28/2021$15.00Buy
    BTIG Research
    More analyst ratings

    $AREB
    $KAVL
    $PBM
    $RELI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Hrt Financial Lp bought $2,776,489 worth of Class A Shares (230,223 units at $12.06) and sold $2,417,788 worth of Class A Shares (181,652 units at $13.31) (SEC Form 4)

    4 - AMERICAN REBEL HOLDINGS INC (0001648087) (Issuer)

    4/9/25 11:26:05 AM ET
    $AREB
    Plastic Products
    Industrials

    Chairman and CEO Beyman Ezra was granted 249,000 shares, covered exercise/tax liability with 55,787 shares and bought $8,502 worth of shares (30,000 units at $0.28), increasing direct ownership by 73% to 527,100 units (SEC Form 4)

    4 - Reliance Global Group, Inc. (0001812727) (Issuer)

    6/28/24 6:10:12 AM ET
    $RELI
    Specialty Insurers
    Finance

    Amendment: Chairman and CEO Beyman Ezra disposed of 289,277 shares, acquired $43,003 worth of shares (356,020 units at $0.12), was granted 168,000 shares, covered exercise/tax liability with 88,382 shares, bought $50,220 worth of shares (186,000 units at $0.27) and gifted 96,667 shares, increasing direct ownership by 694% to 303,886 units (SEC Form 4)

    4/A - Reliance Global Group, Inc. (0001812727) (Issuer)

    6/28/24 6:06:37 AM ET
    $RELI
    Specialty Insurers
    Finance

    $AREB
    $KAVL
    $PBM
    $RELI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sharecare downgraded by BTIG Research

    BTIG Research downgraded Sharecare from Buy to Neutral

    4/1/24 7:41:16 AM ET
    $SHCR
    Medical/Nursing Services
    Health Care

    Morgan Stanley initiated coverage on Sharecare with a new price target

    Morgan Stanley initiated coverage of Sharecare with a rating of Equal-Weight and set a new price target of $2.50

    7/20/22 7:54:21 AM ET
    $SHCR
    Medical/Nursing Services
    Health Care

    Goldman initiated coverage on Sharecare with a new price target

    Goldman initiated coverage of Sharecare with a rating of Neutral and set a new price target of $4.50

    2/11/22 7:17:08 AM ET
    $SHCR
    Medical/Nursing Services
    Health Care

    $AREB
    $KAVL
    $PBM
    $RELI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder

    NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a clinical-stage biopharmaceutical company developing nature-derived psychedelic therapeutics, today announced that the first patient has been dosed in its Phase IIb clinical trial evaluating NPX-5 (25mg of nature-derived psilocybin) for the treatment of Adjustment Disorder in patients with cancer in a palliative care setting. The initiation of dosing represents the first active clinical evaluation of NPX-5 at scale and marks the Company's transition into systematic human data generation across its Australian clinical network. NPX-5 is a GMP-compliant, nature-derived psi

    4/23/26 7:00:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source

    NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a clinical-stage biopharmaceutical company advancing nature-derived psychedelic therapies and manufacturing pharmaceutical-grade drug candidates, today provided an update on its strategic position in the global ibogaine market, as regulatory and clinical interest in the compound continues to expand. Recent signals from U.S. policymakers and global health authorities reflect increasing recognition of the need for structured, evidence-based evaluation of ibogaine, particularly in areas where existing treatment options remain limited. In anticipation of this shift, Psyence B

    4/20/26 7:42:20 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine

    NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a clinical-stage biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies, today acknowledged recent reports that the U.S. administration is preparing an executive order to further evaluate the safety and therapeutic potential of ibogaine, a naturally occurring compound being studied for its potential in treating post-traumatic stress disorder (PTSD), addiction, and other serious neurological and mental health conditions. The anticipated executive action reflects growing recognition of the need for rigorous, regulated research into novel therap

    4/17/26 9:15:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AREB
    $KAVL
    $PBM
    $RELI
    SEC Filings

    View All

    SEC Form 6-K filed by Psyence Biomedical Ltd.

    6-K - PSYENCE BIOMEDICAL LTD. (0001985062) (Filer)

    4/23/26 4:15:15 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14C filed by American Rebel Holdings Inc.

    DEF 14C - AMERICAN REBEL HOLDINGS INC (0001648087) (Filer)

    4/21/26 8:30:36 AM ET
    $AREB
    Plastic Products
    Industrials

    SEC Form 6-K filed by Psyence Biomedical Ltd.

    6-K - PSYENCE BIOMEDICAL LTD. (0001985062) (Filer)

    4/20/26 8:25:16 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AREB
    $KAVL
    $PBM
    $RELI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Morris Eric

    4 - Kaival Brands Innovations Group, Inc. (0001762239) (Issuer)

    4/7/26 4:20:42 PM ET
    $KAVL
    Other Consumer Services
    Consumer Discretionary

    SEC Form 4 filed by Mosser Eric

    4 - Kaival Brands Innovations Group, Inc. (0001762239) (Issuer)

    4/7/26 4:18:41 PM ET
    $KAVL
    Other Consumer Services
    Consumer Discretionary

    SEC Form 4 filed by Thoenes Mark L

    4 - Kaival Brands Innovations Group, Inc. (0001762239) (Issuer)

    4/7/26 4:17:08 PM ET
    $KAVL
    Other Consumer Services
    Consumer Discretionary

    $AREB
    $KAVL
    $PBM
    $RELI
    Financials

    Live finance-specific insights

    View All

    From Super Fibers to Super Deals: Science, Scale, and Strategic Capital Shape the Morning Tape

    DENVER, Dec. 19, 2025 (GLOBE NEWSWIRE) -- This morning's market narrative spans futuristic materials, transformational biotech M&A, and creative capital restructuring, underscoring how innovation-driven companies are pairing long-term vision with near-term execution. Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB): Spider Silk Moves From Legend to Industrial Reality Kraig Biocraft Laboratories set a distinctive tone with a detailed Christmas shareholder letter that framed 2025 as the company's inflection year, marking its transition from prolonged development into early commercialization of recombinant spider silk. The operational message was concrete, as Kraig Labs highlighted major adv

    12/19/25 9:48:44 AM ET
    $FOLD
    $PBM
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Reliance Global Group (RELI) Adds to Zcash (ZEC) Position, and Continues Implementing Its Institutional ZEC Adoption Strategy

    LAKEWOOD, NJ, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Reliance Global Group, Inc. (NASDAQ:RELI) ("Reliance", "we" or the "Company") today announced that it has deployed additional cash to increase its Zcash (ZEC) position. This additional allocation to the Company's Digital Asset Treasury ("DAT") reflects the Company's internal view that ZEC may be an institutionally adaptable and technologically resilient privacy-enabled digital asset and may play a meaningful role in its long-term treasury strategy. Zcash's dual architecture which combines transparent auditability with optional privacy in the Company's view supports its appeal to organizations seeking digital assets that can be implemented fo

    12/8/25 2:40:00 PM ET
    $RELI
    Specialty Insurers
    Finance

    Reliance Global Group Increases Zcash (ZEC) Position Through Additional Cash Deployment

    LAKEWOOD, NJ, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Reliance Global Group, Inc. (NASDAQ:RELI) ("Reliance", "we" or the "Company") today announced that it has deployed additional cash into its Zcash (ZEC) position, as part of its focused Digital Asset Treasury ("DAT") strategy. This step follows Reliance's recent consolidation of its digital asset holdings into Zcash and reflects the Company's current view of ZEC as its primary digital asset exposure within that strategy. Zcash's architecture, featuring a Bitcoin-based security model enhanced with optional privacy and selective disclosure, continues to distinguish it from other blockchain networks. Its dual-transaction model provides transpare

    11/26/25 9:30:00 AM ET
    $RELI
    Specialty Insurers
    Finance

    $AREB
    $KAVL
    $PBM
    $RELI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Psyence Biomedical Ltd.

    SC 13G - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/13/24 9:16:01 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Kaival Brands Innovations Group Inc.

    SC 13D/A - Kaival Brands Innovations Group, Inc. (0001762239) (Subject)

    12/12/24 7:22:30 PM ET
    $KAVL
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Psyence Biomedical Ltd.

    SC 13G/A - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/9/24 1:36:43 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AREB
    $KAVL
    $PBM
    $RELI
    Leadership Updates

    Live Leadership Updates

    View All

    Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone

    NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company") today reinforced how its strategic investment in PsyLabs strengthens its control over pharmaceutical-grade manufacturing and commercial supply chain infrastructure – a critical differentiator in the rapidly expanding psychedelic pharmaceutical sector. Through its investment in PsyLabs, Psyence BioMed has secured: A licensed, owned, and debt-free production operation.Source-level ibogaine supply.Natural psilocybin supply.GMP-compliant manufacturing capabilities.Intellectual property protection.Integrated analytical and chemistry laboratory infrastructure.A capital structur

    3/11/26 9:15:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders

    NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the voting results from its Annual and Special Meeting of Shareholders (the "Meeting"), held at 9:00 a.m. Eastern Time on February 12, 2026. Shareholders voted in favour of all matters of business presented at the Meeting, including the election of directors, the appointment of auditors and the approval of share consolidation authority for the board of directors (the "Board"). All director nominees listed in the Company's management informat

    2/17/26 9:15:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash

    NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced a significant scientific and manufacturing achievement. Through its investment in PsyLabs, Psyence BioMed has become the first Nasdaq-listed company to produce GMP-compliant, high-purity ibogaine hydrochloride (Ibogaine HCl) derived from a naturally extracted, ethically sourced supply in Africa. Ibogaine HCl is the purified, stabilised, crystalline salt form of ibogaine used in clinical and therapeutic settings and represents the standard ph

    1/5/26 9:15:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care